On November 11, 2025, Quoin Pharmaceuticals announced it achieved target rapamycin loading concentrations of 4% and 5% in its topical formulations and dermal patch system, respectively, and plans to begin clinical trials in 2026. This event is significant for the company as it progresses in developing treatments for conditions with no FDA approved options.